可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Li T, Hu J, Thomas JA, et al.Differential induction of apoptosis by LPS and taxol in monocytic cells [J].Mol Immunol, 2005, 42(9):1049-1055.
[2] Yang X, Coriolan D, Murthy V, et al. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient toll-like receptor 4 signaling[J]. Am J Physiol Heart Circ Physiol, 2005, 289(3):H1069-H1076.
[3] Miller YI, Viriyakosol S, Binder CJ,et al.Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells[J]. J Biol Chem, 2003, 278(3):1561-1568.
[4] Walton KA, Hsieh X, Gharavi N,et al.Receptors involved in theoxidized1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8: a role for toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein[J]. J Biol Chem, 2003, 278(32):29661-29666.
[5] Tan MH, Sun Z, Opitz SL, et al. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis[J]. Blood, 2004, 104(1):11-18.
[6] Michelsen KS, Wong MH, Shah PK, et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E[J]. Proc Natl Acad Sci U S A, 2004, 101(29):10679-10684.
[7] Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways[J]. Nat Med, 2004, 10(4):416-421.
[8] Yilmaz A, Lochno M, Traeg F,et al.Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques[J]. Atherosclerosis, 2004, 176(1):101-110.
[9] Hollestelle SCG, de Vries MR, van Keulen JK, et al. Toll- like receptor 4 is involved in outward arterial remodeling[J]. Circulation, 2004, 27(109):393-398.
[10]马克娟,马克威,赵利华. Toll样受体4和肿瘤坏死因子α mRNA在动脉粥样硬化中表达的相关性研究[J]. 中华心血管病杂志, 2004, 32(10):899-902.
[11]Ameziane N, Beillat T, Verpillat P, et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events[J]. Arterioscler Thromb Vasc Biol, 2003, 23(12):e61-e64.
[12]Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events[J]. Circulation, 2003, 107(19):2416-2421.
[13]Edfeldt K, Bennet AM, Eriksson P,et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction[J]. Eur Heart J, 2004, 25(16):1447-1453.
[14]Netea MG, Hijmans A, van Wissen S, et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia[J]. Eur J Clin Invest, 2004, 34(2):94-99.
[15]Yang IA, Holloway JW, Ye S, et al. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis[J].Atherosclerosis, 2003, 170(1):187-190.
[16]Zee RY, Hegener HH, Gould J, et al. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis[J]. Stroke, 2005, 36(1):154-157.